Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at Wells Fargo & Company
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) was upgraded by Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm currently has a $170.00 target price on the specialty pharmaceutical company’s stock, up from their prior target price […]
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) was upgraded by Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm currently has a $170.00 target price on the specialty pharmaceutical company’s stock, up from their prior target price […]
